FDA
-
-
-
-
-
-
-
Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med
-
-
-
-
-
-
-
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
-
-
-
-
-
-
-
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
-
-
-
-
-
-
-
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
-
-
-
-
-
-
-
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
-
-
-
-
-
-
-
Biohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Enters Into Agreement With Genpharm for Distribution of NURTEC ODT in the Middle East
-
329,393 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

